Obermatt
See Similar Stocks →

Unicycive Therapeutics

NAQ:UNCY · US90466Y2028
BiotechnologyX-Small

360° View

85
Price/Sales94
Price/Earnings8
Price/Book100
Dividend Yield100
Revenue Growth1
Profit Growth100
Capital Growth100
TSR 52w20
Leverage60
Liquidity21
Refinancing11
Combined85
Analyst Opinions58
Pro Holdings31
Opinion Changes50
Market Pulse54

Profile

CountryUSA
IndustryBiotechnology
SizeX-Small
TypePublic Company
ExchangeNASDAQCM
Founded2016
Employees24
Websiteunicycive.com
ISINUS90466Y2028
Last UpdateApr 2, 2026
Index & Theme
InflammationNephrologyChronic DiseasesBiotechnologyHealth CareHealth DiagnosticsMedical

Description

Unicycive Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company focus on identifying, developing, and commercializing innovative therapies to address significant unmet medical needs, with an initial focus on kidney diseas…

Analysis

Unicycive Therapeutics's 360° View rank of 85 places it among the strongest overall — better than 85% of its true peers.

It's a growth standout (92) and looks cheap versus peers (97). On safety it is highly leveraged (10), and the market shows muted sentiment (47). Taken together, its Combined rank of 85 reads as among the strongest overall.

360° rank · history

1007550250
85
2026

All-time high

85

Jun 2026

All-time low

58

Mar 2026

Average rank

72

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
94
—
—
—
Price/Earnings
8
—
—
—
Price/Book
100
—
—
—
Dividend Yield
100
—
—
—
Value (overall)
97
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Unicycive Therapeutics with its peers
RAPT Therapeutics
NMQ:RAPT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Ardelyx
NMQ:ARDX
82
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Sagimet Biosciences
NMQ:SGMT
59
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Disc Medicine
NMQ:IRON
5
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mineralys Therapeutics
NSQ:MLYS
21
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Larimar Therapeutics
NMQ:LRMR
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →